Robot Umanoidi nel MedTech

What long seemed like a distant vision of the future is increasingly becoming an industrial reality: “physical AI” is making artificial intelligence capable of acting in the physical world. Robots can now perceive their surroundings, handle objects, respond to deviations, and perform tasks directly in real production environments. Yet despite the first pilot projects in the automotive industry, medical technology – or MedTech – is still hesitant to deploy them more broadly. In the long term, humanoid robots could close a structural automation gap in MedTech production. They come into play precisely where highly standardized processes are already automated efficiently, while recurring, operationally critical tasks still depend entirely on human availability.

The Limits of Traditional Automation

MedTech manufacturing is shaped by complex processes, strict quality standards, and regulatory requirements, while at the same time remaining labor-intensive and difficult to scale in many areas.¹ It is precisely this combination that makes production systems vulnerable: operational disruptions immediately translate into output instability and limited planning reliability. Demographic change and a shortage of young talent are pushing costs up further, placing additional strain on workforces and already forcing 34 percent of companies to reduce services or turn down orders.² The German Economic Institute (Institut der deutschen Wirtschaft) puts the overall economic costs at up to 74 billion euros by 2027.³ For MedTech production, this is particularly critical: sickness-related absences, employee turnover, and training efforts directly threaten production stability and, ultimately, the reliable provision of medical care.⁴ Automation is the obvious lever for countering this pressure. Where processes are stable and standardized, traditional automation demonstrably improves quality, efficiency, and output reliability at the same or lower cost. Yet in MedTech production, this approach reaches its limits. The reason lies in the production reality of the industry. Alongside clearly standardized steps, many activities are characterized by high product variety, frequent changeovers, and manual handling. This so-called high-mix, low-volume pattern is particularly common in implant, kit, and diagnostics assembly. In addition, the regulatory burden is substantial. Every change to automated equipment requires renewed process validation across installation qualification, operational qualification, and performance qualification – IQ, OQ, and PQ. Depending on complexity, the costs range from 10,000 to more than 200,000 US dollars.⁵ The consequence is that many systems are deliberately left unchanged to avoid costly revalidation. Flexibility is therefore structurally penalized. In regulated, high-variety environments, traditional automation tends to fail less because of technical limitations than economic viability.

This is exactly where the potential of humanoid robots becomes apparent. Their decisive strength does not lie in optimizing individual high-performance processes, but in their ability to take over varied, recurring tasks in existing environments designed for humans – without extensive conversions or new validation cycles. Fraunhofer IPA describes this capability as particularly far-reaching, since the combination of possible changes in location and flexible gripping technology enables tasks in existing systems to be automated with minimal integration effort.⁶

How Economical Are Humanoid Robots?

Humanoid robotics has moved beyond the pure research phase and is reaching the threshold of industrial pilot readiness. Initial figures from early production deployments underline this development. The “Figure F.02” robot from the US robotics company Figure AI was used for eleven months at the BMW Group’s Spartanburg plant. During that period, it completed more than 1,250 operating hours, moved over 90,000 car body components, and contributed to the production of more than 30,000 vehicles. It achieved a target accuracy of less than five millimeters. In parallel, the humanoid robot Digit from Agility Robotics was deployed in continuous commercial operation at GXO Logistics’ logistics center. There, it moved more than 100,000 containers, marking the first formal deployment of humanoid robots in the sector.⁷

Both pilot projects show a clear pattern: humanoid robots are currently taking on primarily repetitive and physically demanding tasks in structured environments. These include material handling, machine tending, and simple pick-and-place processes. The same types of activities are also central to MedTech production. Analyses by Porsche Consulting show that, over the medium term, the automation potential of humanoid robots could reach up to 60 percent in assembly and around 35 percent in kitting. However, these figures describe future potential under favorable assumptions, not what is realistically achievable today. Over time, humanoid robots could be deployed without structural modifications and make use of existing shelves, as well as trolleys and tools. Integrated camera systems could also enable real-time validation of components, contributing to the reduction of mix-ups.⁸

A similar picture emerges in machine tending. Humanoid robots can take over loading and unloading processes on existing equipment without requiring production lines to be adapted. In regulated environments, this is a decisive advantage, since every structural change triggers a costly validation cycle.

Short Payback, Limited Maturity

With current acquisition costs of around 55,000 euros per unit and annual operating and maintenance costs of about 5,800 euros, Porsche Consulting calculates a payback period of around 1.5 to 2 years at 100 percent performance capacity. Goldman Sachs and Bank of America confirm the overall direction: both institutions estimate a realistic payback period of 18 to 24 months at Western procurement prices – with a significant reduction once unit costs decline further. Goldman Sachs forecasts a reduction in component costs of around 40 percent per year, gradually lowering the economic threshold for broad deployment.⁸

At a global level, Porsche Consulting estimates that humanoid robots could unlock cost-saving potential of more than 14.3 billion euros in MedTech production by 2030. Despite this economic outlook, the technology is still developing in key areas. Intelligence and perception are approaching human levels, while dexterity and battery life remain the main bottlenecks. Fraunhofer IPA identifies flexible robotic hands as the biggest current hardware bottleneck – a finding that, for the time being, limits their use in MedTech processes requiring fine motor skills, such as implant or catheter assembly.⁹ Even for highly standardized process steps such as assembly, kitting, and intralogistics, Porsche Consulting currently does not yet consider industrial maturity to have been reached. In 2026, the cost-benefit ratio of humanoid robots is not yet sufficient to replace established conventional robotics solutions across the board in these areas.

Fraunhofer IPA assumes that 74 percent of the industrial companies surveyed consider humanoid robots deployable within a time horizon of three to ten years. From an economic perspective, and against the backdrop of the persistent skilled labor shortage, the use of humanoid robots is therefore evolving from a vision of the future into a calculable investment decision.⁹ For MedTech manufacturers in high-wage countries, their deployment could become a central building block for securing production capacity and remaining competitive over the long term.

From Pilot Phase to Operational Necessity

MedTech production is approaching a structural crossroads. Skilled labor shortages, regulatory requirements, and the limits of traditional automation are creating pressure that existing means alone can hardly absorb. Humanoid robots are no longer purely a technology of the future. Early pilot projects show that they can, in principle, operate with stability and economic viability in real production environments, even though this still requires considerable human intervention and cost today. As the cost curve is expected to continue declining, their use for MedTech manufacturers in high-wage countries is likely to become less of a strategic option over the medium term and more of an operational necessity. Those who shape this transition early will not only secure production capacity, but also the planning reliability and supply security on which dependable medical care depends.